Menu
  • The 5th annual E-Cigarette Summit will take place on Friday 17th November at The Royal Society, London
  • Registration for the E-Cigarette Summit 2017 is now open

2017 Speakers

 

Deborah Arnott
Deborah Arnott

Chief Executive, Action on Smoking and Health (ASH)

Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the NICE Programme Development Group which developed the guidance on tobacco harm reduction and of the Commission on Human Medicines expert advisory group to the MHRA on nicotine containing products.  She also has experience of product regulation under the EU General Product Safety Directive having participated in the development of fire safety requirements for cigarettes.

Deborah has an MBA from Cranfield, is an honorary Associate Professor at the University of Nottingham, and a member of the Royal College of Physicians Tobacco Advisory Group.  She was awarded the Alwyn Smith prize in 2007 by the Faculty of Public Health for her outstanding contribution to public health.

Competing Interest: None Stated

Professor Linda Bauld
Professor Linda Bauld

Professor of Health Policy, University of Stirling, UK Centre for Tobacco and Alcohol Studies (UKTAS) and Cancer Research UK

Linda Bauld is Professor of Health Policy, Director of the Institute of Social Marketing and Dean of Research at the University of Stirling. She is also a Deputy Director of the UK Centre for Tobacco and Alcohol Studies and holds the Cancer Research UK/BUPA Chair in Behavioural Research for Cancer Prevention. She has conducted applied research on smoking and smoking cessation for 17 years and is a former scientific adviser on tobacco control for the UK government. She chaired the NICE programme development group on tobacco harm reduction and is involved in ongoing research on this topic.

Competing Interest: None Stated

Dr Tim Baxter
Dr Tim Baxter

Deputy Director for Healthy Behaviours, Department of Health (DoH)

Dr Tim Baxter is Deputy Director for Healthy Behaviours at the Department of Health in London, a position he has held since summer 2016. His work covers alcohol, drugs, nutrition, physical activity for adults, sexual and reproductive health and tobacco control.

Tim joined the Department of Health in 1991 after completing academic research. Since then, he has worked in a range of policy roles, including tobacco control, mental health and primary care policy, run a judicial inquiry and led work on legislation. He also worked on several change management programmes. Tim worked within the National Health Service for eighteen months, including a year as Director of Strategy at University Hospital Lewisham NHS Trust, and then led a review of the UK response to the 2009 Influenza Pandemic. After returning to the Department in 2010, Tim led the reforms to the public health system in England before working on the response to Ebola and taking forward work on global health security.

Martin Dockrell
Martin Dockrell

Tobacco Control Programme Lead, Publich Health England

Martin is Tobacco Control Programme Lead for Public Health England. He joined PHE in February after 7 years at Action on Smoking and Health. Martin has worked in Public Health since the mid 1980’s when he was involved in HIV prevention work. He is a fellow of the Royal Society of Public Health.

Prof Amy Fairchild
Prof Amy Fairchild

Associate Dean of Academic Affairs, Public Health Texas A&M University

 

Dr Konstantinos Farsalinos M.D
Dr Konstantinos Farsalinos M.D

Research Fellow, Onassis Cardiac Surgery Greece, Department of Pharmacology, University of Patras, Greece

Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens, Greece, and at the Department of Pharmacy, University of Patras, Greece. He has been conducting laboratory and clinical research on e-cigarettes as principle investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. He ran a worldwide online survey of almost 20,000 vapers (users of e-cigarettes) identifying patterns of use and experience with e-cigarettes among consumers, published in 2014. He has presented his research findings at major international scientific congresses and his research was used in preparing the regulatory framework on e-cigarettes by the European Union. As of 2016, he has published more than 40 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes

Competing Interest: For some of the studies, the institution has received funding from e-cigarette companies. None of the researchers received any compensation for participating to the studies.

David M. Graham
David M. Graham

Chief Impact Officer, NJOY

David Graham is Chief Impact Officer at NJOY, a role which leads efforts across the company to maximize the positive impact on public health of the company’s products and services through increasing their reach and effectiveness while including oversight of regulatory affairs for the company. He has extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning with nicotine replacement therapy (NRT)/smoking cessation products in the UK in 1992, followed by International product and category development roles in Sweden, he moved to the USA in 2000 with Pharmacia, subsequently becoming part of Pfizer and then moving to Johnson & Johnson.

In 2013, he joined NJOY to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA, and other regulatory agencies internationally, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA’s extension of the PMTA compliance deadline, David returned to NJOY in August 2017 in his current role.

David is a graduate of Columbia University with a Master’s in Public Policy & Administration.

Prof Wayne Hall
Prof Wayne Hall

Professor, Centre for Youth Substance Abuse, Queensland

Wayne Hall is a Professor at the Centre for Youth Substance Abuse Research (CYSAR) at the University of Queensland (January 2014-) and a Visiting Professor at the National Addiction Centre, Kings College London (2009-); the London School of Hygiene and Tropical Medicine (2010-); and the National Drug and Alcohol Research Centre, UNSW.

Wayne was formerly Director of CYSAR (2014-2016), an NHMRC Australia Fellow in addiction neuroethics at the University of Queensland Centre for Clinical Research and the Queensland Brain Institute, UQ (2009-2015); Professor of Public Health Policy in the School of Population Health (2005-2010); Director of the Office of Public Policy and Ethics at the Institute for Molecular Bioscience (2001-2005) at the University of Queensland; and Director of the National Drug and Alcohol Research Centre, UNSW (1994-2001).

In 2010 Wayne was the Wellcome Lecturer at The Centre for Neuroethics, University of Oxford, and received the Lee Greenaway Award from the Alcohol and Drug Foundation, Queensland. Wayne was appointed to the editorial board of Public Library of Science Medicine in 2012.

Wayne has advised the World Health Organization on: the health effects of cannabis use; the effectiveness of drug substitution treatment; the scientific quality of the Swiss heroin trials; the contribution of illicit drug use to the global burden of disease; and the ethical implications of genetic and neuroscience research on addiction.

Dr Jamie Hartmann-Boyce MA, DPhil
Dr Jamie Hartmann-Boyce MA, DPhil

Senior Researcher (Health Behaviours), Managing Editor (Cochrane Tobacco Addiction Group), Nuffield Department of Primary Care Health Sciences, University of Oxford

Jamie Hartmann-Boyce is a senior researcher in health behaviours and managing editor of the Cochrane Tobacco Addiction Review Group, based at the Nuffield Department of Primary Care Health Sciences, University of Oxford. Her research focusses on interventions to combat tobacco addiction and obesity, with a particular focus on evidence synthesis (both quantitative and qualitative) and research impact, through both guideline development and public engagement. As a managing editor for the Cochrane Tobacco Addiction Review Group, Jamie assists in the promotion and dissemination of the Group’s work, authors a number of the group’s reviews, and is a member of the Cochrane Bias Methods Group. Her obesity work is currently funded through the Obesity, Diet and Lifestyle theme of the Oxford Biomedical Research Centre. She has an MA in the history of medicine, where her work explored the tobacco industry’s influence on discourses about personal responsibility for health in the 1950s and 60s. Her DPhil research focussed on the self-management of weight.

Sarah Jakes
Sarah Jakes

Vaper - Board Member, New Nicotine Alliance

Since leaving school ‘a very long time ago’ Sarah Jakes has worked in the shipping industry, the foreign exchange market and now runs her own business in property management.

A smoker of some 35 years Sarah switched to vaping in April 2013, only to find that the choice of this safer alternative for smokers was under threat from excessive and ill founded regulation. Having joined forces with other consumers in the battle against over regulation in the EU parliament Sarah is convinced that a better understanding of e-cigarettes and other harm reduced products among key influencers and decision makers is required if these products are ever to reach their full potential for public health gains.

Beryl Keeley
Beryl Keeley

E-cigarette Notification Scheme Lead, (MHRA) The Medicines and Healthcare Products Regulatory Agency

Beryl Keeley has a background in biochemistry and has worked in various areas in Government and previously in the pharmaceutical industry.  Currently Beryl is Advertising Standards Unit Manager within the Vigilance and Risk Management of Medicines Division of the Medicines and Healthcare products Regulatory Agency.  The Unit has responsibility for the regulation of medicines advertising in the UK.  In this capacity Beryl has worked extensively to promote high standards in all medicines, and recently has been working with industry on the first product that fulfils the official definition of an e-cigarette to go through medicines licensing procedures and receive a marketing authorisation.

Beryl and the MHRA team are responsible for implementing the e-cigarette notification scheme and new regulatory framework under Article 20 of the Tobacco Products Directive.  She brings experience in public perception and industry engagement around Nicotine Replacement Therapy and other medicines to the new functionality of MHRA in regulating e-cigarettes and consumer products.   Understanding the clear and important differences between licensed NRT and the consumer products that make up the vast majority of the vaping industry serves an important purpose in Government plans for implementation and the introduction of a separate regulatory framework

Prof David Levy
Prof David Levy

Professor, Lombardl Comprehensive Cancer Center, Georgetown University

David Levy has a PhD from UCLA in Economics. He is currently a Professor of Oncology at Georgetown. He has published over 200 papers, including articles in the American Economic Review, American Journal of Public Health, JAMA, Lancet, Medical Care, American Journal of Preventive Medicine, Obesity Review, Tobacco Control, and the Review of Economics and Statistics.

He has been principal investigator of grants from the Centers for Disease Control and Prevention, the World Health Organization, the National Cancer Institute, the National Institute on Drug Abuse, Bloomberg/Gates Foundation, European Union, and the Robert Wood Johnson Foundation.  He is currently PI of grants from NCI’s CISNET program and NIDA. Dr. Levy oversees the design and development of the SimSmoke tobacco policy simulation model, which predicts the effect of tobacco policies, such as tax increases, smoke-free air laws, media campaigns, youth access policies, and cessation treatment policies, on smoking rates and tobacco-related deaths. He has developed models for the 10 states and for over 40 countries.

Professor Ann McNeill
Professor Ann McNeill

Professor of Tobacco Addiction, UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London

Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998.

She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies.

Competing Interest: None Stated

Matthew Moden
Matthew Moden

MD Liberty Flights, Chairman of IBVTA Manufacturers and Importers Committee

Matthew Moden is the Honorary Secretary of the IBVTA and Chairman of the IBVTA Manufacturers and Importers Committee.  Matthew is the Managing Director of Liberty Flights, co-founding the business in 2009.  Matthew’s career began in broadcasting with the BBC and evolved into new media and commercial digital spheres. Matthew’s experience and holistic approach to the Vaping sector has led him to implement successful business models in manufacture, retail and wholesale.

Robert Morrison
Robert Morrison

Senior Regulatory Policy Executive, Committee of Advertising Practice

Robert is responsible for advising the Committees of Advertising Practice (CAP) on a range of regulatory policy issues, many of which concern public health. In 2014 he project-managed the consultation and implementation of advertising rules for e-cigarettes and he will be running the scheduled review of those rules later in 2015. He joined CAP from the Advertising Standards Authority’s (ASA) investigations team where he was responsible for examining alleged breaches of the Advertising Codes. Prior to working in advertising regulation he worked as a producer on a range of investigative and consumer television programmes for the major broadcasters

Professor Riccardo Polosa
Professor Riccardo Polosa

Director, Institute of Internal Medicine and Clinical Immunology, University of Catania

Professor Riccardo Polosa is Director of the Institute for Internal and Emergency Medicine of the University of Catania in Italy.  He is also in charge of the University’s Centre for Tobacco Research (CPCT), and Honorary Professor of Medicine at Southampton University (UK).  He is author of more than 250 peer reviewed articles and books mainly covering repiratory medicine, clinical immunology, and tobacco addiction.  Professor Polosa and his research team have lead several clinical trials on e-cigarettes.

On top of his academic work, he serves also as Chief Scientific Advisor for Lega Italiana Anti Fumo (LIAF), the Italian Anti-Smoking League.

CONFLICT OF INTERESTS:

Riccardo Polosa has received lecture fees and research funding from GlaxoSmithKline and Pfizer, manufacturers of stop smoking medications.

He has also served as a consultant for Pfizer and Arbi Group Srl (Milano, Italy), the distributor of Categoria™ e-Cigarettes. His research on electronic cigarettes is currently supported by LIAF (Lega Italiana AntiFumo).

 

Louise Ross
Louise Ross

Stop Smoking Service Manager, Leicester City Council

Louise Ross is the Stop Smoking Service Manager for Leicester City.  She has worked in smoking cessation and tobacco control for ten years. Previously she had managed a large care home for people with learning disabilities for almost 30 years, and this career change, an opportunity that disproves the theory that one needs a life-plan to be happy, has been a fantastic opportunity to influence people’s health for the better.

Initially suspicious of e-cigs, her epiphany moment happened at the 2013 E-Cigarette Summit (around lunchtime), and since then she has been a committed advocate of listening to what the general public, and Stop service users in particular, are saying about their experiences of vaping.

Competing Interest Louise has not personally received any funding from external sources but Leicester Stop Smoking Service has received contributions from GSK, Pfizer, Johnson & Johnson for example in terms of training lunches for Level 2 advisors.

Dr Lion Shahab
Dr Lion Shahab

Senior Lecturer in Health Psychology, University College London (UCL)

Dr Shahab is a senior lecturer in health psychology at University College London and trained in psychology, epidemiology and neuroscience. He has more than 10 years’ experience in tobacco control with a particular interest in novel behavioural and pharmacological smoking cessation interventions, biomarkers, tobacco product regulation and policy and tobacco use epidemiology.

Dr Ed Stephens
Dr Ed Stephens

Senior Research Fellow, University of St Andrews

Ed Stephens completed his undergraduate and doctoral training at the University of Wales, Aberystwyth. On moving to the University of St Andrews in Scotland he worked on the geochemistry of magmatic processes that formed the Earth’s continental crust, for which research he was elected to a Fellowship of the Royal Society of Edinburgh. More recently he has realigned his research to applying geochemistry to understanding the pathways and mechanisms by which environmental toxins, particularly the heavy metals, are transferred to the human body by tobacco smoke.

Professor Robert West
Professor Robert West

Professor of Health Psychology & Director of Tobacco Studies, University College London (UCL)

Robert  West is Professor of Health Psychology and Director of Tobacco Studies at the Cancer Research UK Health Behaviour Research Centre, University College London, UK. Professor West is also Editor-in-Chief of the journal Addiction. He is co-author of the English National Smoking Cessation Guidelines that provided the blueprint for the UK-wide network of stop-smoking services that are now an established part of the UK National Health Service. His research includes evaluations of methods of helping smokers to stop and population surveys of smoking and smoking cessation patterns.

Competing Interest:

I undertake research and consultancy for companies that develop and manufacture smoking cessation medications including licensed nicotine products. I am author of the stop-smoking guide ‘The SmokeFree Formula’. My salary is funded by Cancer Research UK.